Mark G Charest

USPTO Granted Patents = 13 (Patent Applications = 1)

CIPO Patents = 5

EPO Patents = 7 (Patent Applications = 4)

Average Co-Inventor Count = 7.0

ph-index = 6

Forward Citations = 119(Granted Patents)

Location History:

Somerville, MA (US) (2010)
Cambridge, MA (US) (2003 - 2013)
Belle Mead, NJ (US) (2013 - 2021)

Company Filing History:

Years Active: 2003-2021

Loading Chart...

13 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11192866 - Synthesis of tetracyclines and analogues thereof (2021-12-07),

2. 10669244 - Synthesis of tetracyclines and analogues thereof (2020-06-02),

3. 9884830 - Synthesis of tetracyclines and analogues thereof (2018-02-06),

4. 9365493 - Synthesis of tetracyclines and analogues thereof (2016-06-14),

5. 8598148 - Synthesis of tetracyclines and analogues thereof (2013-12-03),

6. 8552003 - (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-4-(4-fluorobenzoyl)-thiazol-2-yl]pyrrolidin-1-yl}-2-oxoethyl)-2-methylamino-propionamide, or pharmaceutically acceptable salts thereof and their uses (2013-10-08),

7. 8546336 - SMAC peptidometics useful as IAP inhibitors (2013-10-01),

8. 8338440 - Inhibitors of IAP (2012-12-25),

9. 8207183 - Inhibitors of IAP (2012-06-26),

10. 8044209 - Pyrrolydine derivatives as IAP inhibitors (2011-10-25),

11. 7807842 - Synthesis of tetracyclines and analogues thereof (2010-10-05),

12. 7419975 - Organic compounds (2008-09-02),

13. 6589962 - Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof (2003-07-08),

Title: Mark G Charest: Innovator in Antibiotic Synthesis

Introduction

Mark G Charest is a prominent inventor based in Cambridge, MA, known for his significant contributions to the field of antibiotic synthesis. With a total of 13 patents to his name, Charest has made remarkable advancements in the development of tetracycline antibiotics, which have been crucial in treating infectious diseases for over five decades.

Latest Patents

One of Charest's latest patents focuses on the synthesis of tetracyclines and their analogues. The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of tetracyclines in both human and veterinary medicine has led to resistance among many organisms that were previously susceptible to these antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described in his patent provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines that were previously inaccessible through earlier synthesis and semi-synthetic methods. These analogs may serve as effective anti-microbial agents or anti-proliferative agents in the treatment of diseases affecting humans and other animals.

Career Highlights

Throughout his career, Mark G Charest has worked with notable organizations such as Novartis AG and Harvard College. His work in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research in antibiotic development.

Collaborations

Charest has collaborated with esteemed colleagues, including Christopher Sean Straub and Run-Ming David Wang. These partnerships have further enhanced his research and innovation in antibiotic synthesis.

Conclusion

Mark G Charest stands out as a key figure in the field of antibiotic research, with his innovative approaches to synthesizing tetracyclines and their analogs. His contributions continue to impact the treatment of infectious diseases, showcasing the importance of innovation in medicine.

This text is generated by artificial intelligence and may not be accurate.